| INTRODUCTION
One-third of cirrhotic patients with gastroesophageal varices suffer acute haemorrhage, which increases rates of morbidity and mortality. 1 Nonselective beta-blockers decrease portal blood flow and pressure 2 and are therefore the first-line therapy to reduce the incidence of small and large variceal haemorrhaging. 3 Beta-blockers have been found to effectively reduce the incidence of variceal haemorrhaging and related mortality. 4 Moreover, they also reduce heart rate and cardiac output which are variables central to cardiopulmonary performance. 5 Several studies have demonstrated the prognostic utility of cardiopulmonary performance, as determined by the ventilatory threshold (VT) and peak oxygen uptake ( _ VO 2 ) during cardiopulmonary exercise testing(CPET), to peri-and post-operatively risk stratify liver transplant patients. [6] [7] [8] The oxygen uptake efficiency slope(OUES),
representing a linear depiction of ventilatory efficiency for a given _ VO 2 , has also been shown to be a valid, effort independent, measure of cardiopulmonary performance and may offer utility in quantifying physiological reserve in this population. 9 It is unclear whether betablockers impact CPET-derived variables used in the risk stratification of patients for the development of peri-and post-operative complications. This may potentially affect clinical decision-making related to liver transplantation.
The aim of this investigation was to determine the effects of beta-blocker therapy on CPET-derived variables in patients with advanced liver disease prior to liver transplantation. We hypothesised that patients taking beta-blockers would have a lower VT and peak _ VO 2 compared to those patients not taking the medication. It was also hypothesised that there would be no significant difference in the OUES between the groups. and in hospital until discharge was also recorded.
| PATIENTS AND METHODS
This
| Cardiopulmonary exercise test(CPET)
CPET was performed in accordance with the recommendations proposed by the American Thoracic Society/American College of Chest
Physicians. 10 All patients were fasted for a minimum of four hours and advised to maintain their usual medication dosages as prescribed by their referring physician. Patients prescribed beta-blockers confirmed that they had taken their medication prior to the test. In our centre, Propranolol is the exclusively used prophylaxis for portal hypertension and its associated conditions. The dose ranged between 10 mg and 40 mg twice daily. All patients were titrated under the maximum tolerated dose.
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Standardised calibration methods were followed before each CPET. Pneumotach volume (Hans Rudolph 3L calibration syringe) and gas analysers (two point calibration against two gravimetric gas standards: 21% oxygen, balance nitrogen and 5% carbon dioxide/12% oxygen, balance nitrogen) were calibrated according to manufacturer between beta-blocker and nonbeta-blocker groups was performed using a Chi-squared test. General linear modelling was used to determine the differences in CPET-derived variables for patients on or off beta-blockers, adjusting for potential confounding variables including age (years), the model of end-stage liver disease (MELD) score, liverdisease aetiology and the presence of refractory ascites. Linear regression was performed to explore the ability of CPET variables to predict perioperative time in intensive care and hospital stay. Significance values of P <.1 were included in a multivariate analysis. All analyses were performed using a statistical software package (SPSS, Version 24, IBM, New York, USA) and statistical significance was assumed if P <.05.
| RESULTS
Eighty patients underwent CPET prior to liver transplantation. A total of 72 patients were included in the analysis with eight patients excluded due to insufficient clinical or CPET data. Ten patients did not perform CPET for the following reasons: (1) three patients were deemed clinically fit and were required not to undergo CPET as per the treating hepatologist; (2) two patients presented with musculoskeletal impairments and were unable to cycle; (3) two patients had severe hepatic encephalopathy limiting the ability to perform CPET and (4) reasons were not stated for the remaining three patients. Table 1 beta-blockers and those who were not for all unplanned hospital admissions (P = .87). Table 2 provides a summary of CPET-derived data in those patients receiving or not receiving beta-blocker therapy, without adjusting for covariates. Both groups were able to achieve a similar work rate at VT (P = .73) and at peak exercise (P = .97). Heart rates achieved at VT and at peak exercise were significantly lower in the beta-blocker group (P < .01) compared to the nonbeta-blocker group; this was also evident for all sub-analyses performed (Tables   S1-S4 ). Both the VT (P < .01) and peak _ VO 2 (P = .02) were also significantly lower in the beta-blocker group. For patients without HCC (n = 45), VT (P = .02) and peak _ VO 2 (P <.01) were significantly lower in patients taking beta-blockers(n = 20) compared to those who
were not(n = 25) (Tables S1 and S2 ). In those without refractory ascites (n = 58), patients taking beta-blockers (n = 22) had significantly lower VT (P <.01) compared to patients not taking the medication (n = 36). However, peak _ VO 2 was significantly lower in patients taking beta-blockers who also had refractory ascites (P = 0.02) (Tables S3 and S4 ). There were no significant betweengroup differences in oxygen pulse, the OUES or the VE/ _ VCO 2 slope.
Results from the general linear model for CPET variables measured at VT and at peak exercise are presented in Table 3 and Table 4 respectively. After adjustment for age, MELD score, liverdisease aetiology and the presence of refractory ascites, VT remained significantly lower (P <.05) in patients taking beta-blockers compared to those who were not taking the medication (mean difference 1.2 mL/kg/min). The heart rate achieved at the VT (mean difference 18.4 beats/min) and at peak exercise (mean difference 19.9 beats/min) was also significantly reduced (P <.01) in patients receiving beta-blockers. There were no significant differences between groups for the remaining CPET-derived variables including the OUES (P = .25).
There were no deaths within 90 days following liver transplantation. Patients taking pre-operative beta-blockers had a significantly longer hospital stay (P = .03) and trended towards having a longer time in intensive care following surgery (P = .08). Regression analysis demonstrated that participant age (r = .20, P = .10), MELD score at the time of transplantation (r = .21, P = .07), peak _ VO 2 (r = À.21, P = .07), blood transfusions (r = .52, P <.01) and fresh frozen plasma transfusions during transplant surgery (r = .60, P <.01) were associated with time spent in hospital. Fresh frozen plasma transfusions during transplant surgery was the only variable to retain significance in the multivariate model (R 2 = 0.38, P <.01). The MELD score at the time of CPET (r = .29, P = .02) and at transplantation(r = .47, P <.01), serum sodium (r = À.27, P = .02), the V E/V CO 2 slope (r = .28, P = .02), blood transfusions (r = .33, P <.01) and fresh frozen plasma transfusions (r = .25, P = .04) were univariate predictors of intensive care stay. However, only the MELD score at transplantation retained significance when incorporated into the multivariate regression (R 2 = 0.29, P = .01). The OUES was not significantly associated with these perioperative outcomes.
| DISCUSSION
The aim of this investigation was to determine the effect of betablocker therapy on CPET-derived variables in patients with advanced liver disease prior to liver transplantation. The main finding was that the OUES was not influenced by beta-blockers, unlike VT and peak _ VO 2 . These findings indicate that the use of the OUES as a primary measure of cardiopulmonary performance and potentially clinical status as well as pre-surgical risk stratification may be advantageous.
Patients taking beta-blockers had a higher severity of liver disease and associated complications than those not taking beta- blockers. As expected, these patients also exhibited significantly lower heart rates at VT and peak exercise. When CPET-derived variables were adjusted for confounders, the VT and heart rates achieved at VT and peak exercise continued to be influenced by the medication. However, the OUES was not significantly affected by beta-blockers.
To obtain a valid representation of a patient's true cardiopulmonary performance, temporarily withholding beta-blockers seems logical. The withdrawal of beta-blockers may reveal exercise-related ischaemic changes associated with increased cardiac output.
However, the importance of remaining on medication to reduce short-term post-operative mortality and incidence of cardiovascular events is well recognised. 15 Particularly in the setting of advanced liver disease, there is a theoretical risk of fatal variceal haemorrhaging due to an increased hepatic-venous portal pressure gradient. The importance of CPET as a risk stratification tool prior to liver transplantation is well recognised in the literature. [6] [7] [8] Prentis and colleagues demonstrated that a VT <9 mL/kg/min was associated with an increased risk of 90 days mortality following liver transplantation. 6 The authors found that those who survived 90 days had a CPET, cardiopulmonary exercise test; _ VO 2 , oxygen uptake.
T A B L E 4
The effect of beta-blocker therapy on cardiopulmonary exercise testing-derived variables at peak exercise [adjusted for age (y), model of end-stage liver-disease score, liver-disease aetiology and the presence of refractory ascites] 17 In this study, the VT for patients taking beta-blockers was almost 1.2 mL/kg/min lower compared to those not taking the medication. This would have significant clinical implications for patients who may be deemed at high risk of shortterm post-operative mortality (VT <9 mL/kg/min), but are receiving beta-blocker therapy at the time of CPET. We have shown here that reduced VT is a consequence of beta-blocker therapy, and may not accurately represent cardiopulmonary performance in this cohort.
The negative chronotropic and inotropic impact of beta-blockers on heart rate during exercise in healthy and clinical populations is well established, [18] [19] [20] [21] and was also seen in our patient group. It is understood that patients with advanced liver disease have a hyperdynamic circulation attributed to a reduction in systemic and pulmonary vascular resistance. Patients will also often exhibit impaired cardiac diastolic relaxation, blunted contractile responsiveness and chronotropic incompetence during exercise. 22 The current data suggest the action of beta-blockers in this cohort during exercise reduces heart rate but does not appear to significantly augment stroke volume and arteriovenous oxygen difference(as measured indirectly by oxygen pulse). Therefore, the lower VT achieved by patients taking beta-blockers cannot be fully attributed to the effect of the medication on cardiac physiology. However, there were no significant differences in the OUES or _ VE/ _ VCO 2 slope, also highlighting that beta-blockers do not appear to significantly influence pulmonary perfusion or ventilatory efficiency during exercise in patients with advanced liver disease.
It is likely that this reduction in VT is multifactorial. Nonselective beta-blocker administration causes partial inhibition of beta-adrenergic receptors in the peripheral vasculature. 23 This may lead to an earlier onset of plasma lactate accumulation, increasing reliance on anaerobic metabolism during exertion. 24 Those patients who were receiving beta-blockers also exhibited a greater degree of liver-disease severity, which has also been associated with skeletal muscle atrophy. 25 Advanced liver disease is associated with malnutritioninduced cachexia, up-regulation of inflammatory cytokines, oxidative stress and muscle deconditioning, further facilitating skeletal muscle dysfunction. The combination of these factors likely contributes to the pre-mature onset of anaerobic metabolism and compromised functional performance.
While beta-blockers are used as primary prophylaxis to reduce variceal haemorrhaging in advanced liver disease, there is little data on the impact of these medications on CPET variables. An early investigation by Premaratna and colleagues examined the impact of propranolol combined with isosorbide dinitrate on exercise capacity in patients with alcohol-induced cirrhosis and portal hypertension. 26 They also found a significantly lower heart rate response to exercise in participants taking the beta-blockers. There was no significant difference in submaximal and maximal work capacity, compared to those not taking the medication. These results highlight that the lower heart rate does not appear to limit physical There are a number of limitations associated with the current investigation. It is unclear whether the degree of beta-blockade may have differentially impacted CPET-derived variables. In addition, while all patients were considered chronically beta-blocked, the specific plasma half-life of the medication was not assessed at the time of CPET. Another important limitation is the cross-sectional study design.
The implementation of a randomised, double-blinded, placebo-controlled, cross-over methodology would be ideal to rigorously evaluate the effects of beta-blockers on CPET-derived variables in this cohort.
However, withdrawal of beta-blockers prior to a graded exercise test is likely to increase the risk of variceal haemorrhaging. Finally, while the influence of beta-blockers on CPET variables was the primary objective of this investigation, the interaction with additional medications commonly used in the medical management of this patient cohort (eg, potassium sparing diuretics, loop diuretics) was not explored.
This is the first investigation to demonstrate the negative influence of beta-blocker medication on prognostically relevant CPET markers in patients with advanced liver disease awaiting liver transplantation. After adjusting for potential confounders, we found that patients taking beta-blockers had a significantly lower VT compared to those not taking the medication. As expected, there was also a significant reduction in the heart rate response to exercise. Finally, given the withdrawal of beta-blockers in this cohort is not recommended, the OUES, a variable independent of medication use, could be used to assess cardiopulmonary performance.
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